Enhanced soluble expression of active recombinant human interleukin-29 using champion pET SUMO system

Ahmed N, Afroze B, Abbas R, Khan MA, Akram M, Tahir S, Bakht S, Munir A, Shahid AA (2021) Method for efficient soluble expression and purification of recombinant human interleukin-15. Protein Expr Purif 177:105746. https://doi.org/10.1016/j.pep.2020.105746 Akram M, Khan MA, Ahmed N, Bhatti R, Pervaiz R, Malik K, Tahir S, Abbas R, Ashraf F, Ali Q (2023) Cloning and expression of an anti-cancerous cytokine: human IL-29 gene in Chlamydomonas reinhardtii. AMB Express 13(1):23. https://doi.org/10.1186/s13568-023-01530-1 Ank N, West H, Paludan SR (2006) IFN-λ: novel antiviral cytokines. J Interferon Cytokine Res 26(6):373–379 Balabanov D, Zhao L, Zhu Z, Hunzeker ZE, Tonner HM, Ding VA, Wakefield MR, Bai Q, Fang Y (2019) IL-29 exhibits anti-tumor effect on Pan-48 pancreatic cancer cells by up-regulation of P21 and Bax. Anticancer Res 39(7):3493–3498 Bessette PH, Åslund F, Beckwith J, Georgiou G (1999) Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc Natl Acad Sci 96(24):13703–13708 Bis RL, Stauffer TM, Singh SM, Lavoie TB, Mallela KM (2014) High yield soluble bacterial expression and streamlined purification of recombinant human interferon α-2a. Protein Expr Purif 99:138–146 Burgess-Brown NA, Sharma S, Sobott F, Loenarz C, Oppermann U, Gileadi O (2008) Codon optimization can improve expression of human genes in Escherichia coli: a multi-gene study. Protein Expr Purif 59(1):94–102 Butt TR, Edavettal SC, Hall JP, Mattern MR (2005) SUMO fusion technology for difficult-to-express proteins. Protein Expr Purif 43(1):1–9 Cabrita LD, Dai W, Bottomley SP (2006) A family of E. coli expression vectors for laboratory scale and high throughput soluble protein production. BMC Biotechnol 6(1):1–8 Clark EDB (2001) Protein refolding for industrial processes. Curr Opin Biotechnol 12(2):202–207 De Marco V, Stier G, Blandin S, De Marco A (2004) The solubility and stability of recombinant proteins are increased by their fusion to NusA. Biochem Biophys Res Commun 322(3):766–771 Donnelly RP, Kotenko SV (2010) Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30(8):555–564. https://doi.org/10.1089/jir.2010.0078 Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T, Nakayama K, Numasaki M (2011) Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 102(11):1977–1990. https://doi.org/10.1111/j.1349-7006.2011.02079.x Hamming OJ, Terczyńska-Dyla E, Vieyres G, Dijkman R, Jørgensen SE, Akhtar H, Siupka P, Pietschmann T, Thiel V, Hartmann R (2013) Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 32(23):3055–3065 Hou W, Wang X, Ye L, Zhou L, Yang Z-Q, Riedel E, Ho W-Z (2009) Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 83(8):3834–3842 Hui X, Chen H, Zhang S, Ma X, Wang X, Huang B (2011) Antitumor activities of recombinant human interferon (IFN)-λ1 in vitro and in xenograft models in vivo for colon cancer. Cancer Let 311(2):141–151 Kapust RB, Waugh DS (1999) Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Sci 8(8):1668–1674 Kong B, Guo GL (2011) Enhanced in vitro refolding of fibroblast growth factor 15 with the assistance of SUMO fusion partner. PLoS ONE 6(5):e20307 Kotenko S, Gallagher G, Baurin V, Antes A, Shen M, Shah N, Langer J, Sheikh F, Dickensheets H, Donnelly R (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunol 4:69–77. https://doi.org/10.1038/ni875 Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011) Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol 2011:349575–349575. https://doi.org/10.1155/2011/349575 Lazear HM, Daniels BP, Pinto AK, Huang AC, Vick SC, Doyle SE, Gale M Jr, Klein RS, Diamond MS (2015a) Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med 7(284):284ra259-284ra259 Lazear HM, Nice TJ, Diamond MS (2015b) Interferon-λ: immune functions at barrier surfaces and beyond. Immunity 43(1):15–28 Li M, He S (2006) Purification and characterization of recombinant human interleukin-29 expressed in Escherichia coli. J Biotechnol 122(3):334–340. https://doi.org/10.1016/j.jbiotec.2005.11.019 Li M, Huang D (2007) On-column refolding purification and characterization of recombinant human interferon-λ1 produced in Escherichia coli. Protein Expr Purif 53(1):119–123 Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, Shimada H, Tagawa M (2010) Interferon-λ induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 46(1):180–190 Li JF, Cui XW, Ji HY, Qiu T, Ji XM, Du MX, Wu HT, Xu XZ, Zhang SQ (2011) High efficient expression of bioactive human BMP-14 in E. coli using SUMO fusion partner. Protein J 30(8):592–597 Mahlakoiv T, Ritz D, Mordstein M, DeDiego ML, Enjuanes L, Müller MA, Drosten C, Staeheli P (2012) Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread. J Gen Virol 93(12):2601–2605 Malakhov MP, Mattern MR, Malakhova OA, Drinker M, Weeks SD, Butt TR (2004) SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. J Struct Funct Genomics 5(1):75–86 Marblestone JG, Edavettal SC, Lim Y, Lim P, Zuo X, Butt TR (2006) Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO. Protein Sci 15(1):182–189. https://doi.org/10.1110/ps.051812706 Middelberg AP (2002) Preparative protein refolding. Trends Biotechnol 20(10):437–443 Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T (2014) A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol 61(6):1238–1246 Müller S, Hoege C, Pyrowolakis G, Jentsch S (2001) SUMO, ubiquitin’s mysterious cousin. Nat Rev Mol Cell Biol 2(3):202–210 Nguyen T-Q, Duong T-H, Dang T-N-H, Le N-G, Le Q-G, Do T-H, Nguyen V-D, Le T-T-H, Truong N-H (2018) Enhanced soluble expression and effective purification of recombinant human interleukin-11 by SUMO fusion in Escherichia coli. Indian J Biotechnol 17:579–585 Palma-Ocampo HK, Flores-Alonso JC, Vallejo-Ruiz V, Reyes-Leyva J, Flores-Mendoza L, Herrera-Camacho I, Rosas-Murrieta NH, Santos-López G (2015) Interferon lambda inhibits dengue virus replication in epithelial cells. Virol J 12(1):1–14 Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45(2):164–171 Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS, Hartmann R, Kotenko SV, Lazear HM, O’Brien TR, Odendall C (2020) COVID-19 and emerging viral infections: The case for interferon lambda. J Exp Med. https://doi.org/10.1084/jem.20200653 Rabhi-Essafi I, Sadok A, Khalaf N, Fathallah DM (2007) A strategy for high-level expression of soluble and functional human interferon α as a GST-fusion protein in E. coli. Protein Eng Des Sel 20(5):201–209 Rahman ZU, Ahmed N, Fazal N, Khan MI, Khan MA, Tahir S, Akram M, Ullah S, Zafar AU (2023) Enhancing the expression and purification of IL-29: a study of autoinduction and one-step purification methods. Advancements Life Sci 10(1):122–128 Robek MD, Boyd BS, Chisari FV (2005) Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79(6):3851–3854 Shaldzhyan A, Zabrodskaya Y, Yolshin N, Kudling T, Lozhkov A, Plotnikova M, Ramsay E, Taraskin A, Nekrasov P, Grudinin M, Vasin A (2021) Clean and folded: production of active, high quality recombinant human interferon-λ1. Process Biochem 111:32–39. https://doi.org/10.1016/j.procbio.2021.08.029 Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63–68 Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4(3):e1000017 Stewart EJ, Åslund F, Beckwith J (1998) Disulfide bond formation in the Escherichia coli cytoplasm: an in vivo role reversal for the thioredoxins. EMBO J 17(19):5543–5550 Tezuka Y, Endo S, Matsui A, Sato A, Saito K, Semba K, Takahashi M, Murakami T (2012) Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells. Lung Cancer 78(3):185–192 Wang H, Xiao Y, Fu L, Zhao H, Zhang Y, Wan X, Qin Y, Huang Y, Gao H, Li X (2010) High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol 10(1):1–9 Wang D, Fang L, Zhao F, Luo R, Chen H, Xiao S (2011) Molecular cloning, expression and antiviral activity of porcine interleukin-29 (poIL-29). Dev Comp Immunol 35(3):378–384 Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22(11):1393–1398 Xie YF, Chen H, Huang BR (2007) Expression, purification and characterization of human IFN-λ1 in Pichia pastoris. J Biotechnol 129(3):472–480. https://doi.org/10.1016/j.jbiotec.2007.01.018 Zitzmann K, Brand S, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer CJ (2006) Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 344(4):1334–1341